Medicare beneficiaries face a challenging trade-off as insurers adapt to new federal drug coverage mandates. While the Inflation Reduction Act promised to eliminate the coverage gap and cap annual out-of-pocket costs at $2,000, insurance companies have responded by restructuring their plans in ways that may shift financial burden to the beginning of the coverage year. The analysis reveals substantial deductible increases across Medicare drug plans, with standalone prescription plans raising average deductibles from $385 to $454, representing an 18% jump. Medicare Advantage plans showed even more dramatic changes, with deductibles surging 152% from $99 to $249. These increases effectively frontload costs that were previously distributed throughout the year. Perhaps more concerning for medication access, insurers have fundamentally altered their cost-sharing structures. Medicare Advantage plans dramatically expanded their use of coinsurance arrangements for mid-tier medications, jumping from 6.3% to 38.1% of tier 3 drugs. This shift means patients now pay a percentage of drug costs rather than fixed copayments, creating unpredictable expenses that vary with medication prices. The research highlights a familiar pattern in healthcare policy: regulatory reforms often trigger adaptive responses that can undermine intended benefits. While the $2,000 annual cap provides important protection against catastrophic drug costs, the accompanying deductible increases and structural changes may create new barriers to medication access, particularly for patients with chronic conditions requiring expensive medications early in the coverage year. This dynamic suggests that meaningful drug affordability requires more comprehensive approaches than coverage gap elimination alone.